Skip to content

Characteristics of steroid hormone and proteomic expressions in glaucoma, aqueous humor and plasma

Characteristics of steroid hormone and proteomic expressions in glaucoma, aqueous humor and plasma

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081103
Enrollment
Unknown
Registered
2024-02-22
Start date
2024-03-15
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Glaucoma group :None
Cataract control group:none

Sponsors

Huizhou Third People's Hospital, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 50-80 who need glaucoma and cataract surgery for primary open-angle glaucoma (POAG), primary chronic angle-closure glaucoma (CPACG) and primary acute angle-closure glaucoma (APACG), and suspicious angle-closure (PACS) or primary angle-closure (PAC). This type of eye has not had other internal eye surgeries before, such as intravitreal injection, vitrectomy, cataract, glaucoma surgery, etc. 2. A clear history of primary glaucoma, who has undergone cataract surgery or trabeculectomy, laser periidotomy, etc., and is now hospitalized for simple cataract surgery or glaucoma surgery. 3. The diopter is less than -6D. 4. Have not received corticosteroids, radiotherapy, or chemotherapy in the past 6 months 5. Have not received topical praprofen or hormone eye drops in the past half month

Exclusion criteria

Exclusion criteria: (1) One-eyed (2) Secondary glaucoma: such as neovascular glaucoma, uveitis and trauma; (3) other eye diseases, such as uveitis and trauma; (4) Other hereditary eye diseases of the eye, such as retinitis pigmentosa, etc.; (5) metabolic diseases such as diabetes; (6) or serious diseases, such as rheumatic diseases, immune diseases, lung cancer, adrenal tumors and pituitary tumors, breast cancer, etc.

Design outcomes

Primary

MeasureTime frame
Steroids, hormones ; proteomics;

Countries

China

Contacts

Public ContactShuifeng Deng

Huizhou Third People's Hospital, Guangzhou Medical University

dr_phonix@126.com+86 188 1866 4500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026